Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes associated with mitigating venous thromboembolism risk in pregnant patients with sickle cell disease

View Full Paper
Ask AI
Bookmark
Share

Authors

RARoberta C. G. Azbell

Discussion

Loading...

Member takes

Overview

Retrospective review of anticoagulation effects on postpartum hemorrhage and VTE in pregnant patients with sickle cell disease, suggesting safety of preventive measures.

Key Points

  • Evaluate risks of anticoagulation during pregnancy and postpartum in sickle cell disease patients.
  • Retrospective chart review at Ohio State Wexner Medical Center
  • Identified pregnant patients using ICD-10 codes
  • Compared VTE history and anticoagulation outcomes
  • Applied generalized linear mixed model for categorical variable comparison
  • Conducted univariate and multivariate analyses for postpartum hemorrhage risk
  • Identified 75 pregnancies among 59 patients with median age of 28 years
  • 39 pregnancies received anticoagulation with no significant differences in maternal outcomes
  • VTE episodes occurred primarily with additional provoking factors during pregnancy
  • Postpartum hemorrhage rates were similar between anticoagulated and non-anticoagulated groups
  • Anticoagulation linked to 3% rate of heparin-induced thrombocytopenia, no maternal deaths observed

Cite This Study

Roberta C. G. Azbell (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d036https://doi.org/10.1182/blood-2025-7970
View Full Paper
Ask AI
Bookmark
Share